Rifaximin: Research, Dosing, and Where to Buy in 2026
A research-first profile for Rifaximin (Rifa Mixen), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
Rifaximin is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers for Rifaximin, each linked to its source.
- Also indexed as Rifa Mixen.
- 0 aggregated dosing-protocol mentions from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is Rifaximin?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
Rifaximin Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
No transcript-derived dosing mentions in current source set.
Where to Buy Rifaximin in 2026
No tracked vendor recommendations for Rifaximin yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about Rifaximin. Each line links to the original source.
- "Relative risks (RRs) with 95% confidence intervals (CIs) were applied to calculate pooled effect estimates for the treatment effectiveness of rifaximin plus lactulose versus lactulose alone by using the random-effects model." · Fu J et al, 2022 PubMed
- "We noted that the use of rifaximin plus lactulose was associated with an increased incidence of effective rate than lactulose alone (RR, 1.30; 95% CI, 1.10-1.53; P = 0.002)." · Fu J et al, 2022 PubMed
- "Moreover, the use of rifaximin plus lactulose was associated with a reduced risk of mortality as compared with lactulose alone (RR, 0.57; 95% CI, 0.41-0.80; P = 0.001)." · Fu J et al, 2022 PubMed
- "50% reduction in neutrophil oxidative burst (OB) at 30 days." · Patel V et al, 2022 PubMed
- "Rifaximin-α did not lead to a 50% reduction in spontaneous neutrophil OB at 30 days compared to baseline (p = 0.48)." · Patel V et al, 2022 PubMed
- "Those on rifaximin-α were less likely to develop infection (odds ratio 0.21; 95% CI 0.05-0.96)." · Patel V et al, 2022 PubMed
- "The overall eradication rate according to intention-to-treat analysis (ITT) was 59% (95% CI: 50 to 69%; I2 = 90.69%) and to per protocol analysis (PP) 63% (95% CI: 53 to 72%; I2 = 90.32%)." · Wang J et al, 2021 PubMed
- "For 5 RCTs included comparing the efficacy between rifaximin and placebo or active controls, there was no significant difference (n = 203, risk ratio = 1.14, 95%CI: 0.59 to 2.19, P = 0.15, I2 = 38%)." · Wang J et al, 2021 PubMed
- "Rifaximin significantly reduced the risk of an episode of hepatic encephalopathy, as compared with placebo, over a 6-month period (hazard ratio with rifaximin, 0.42; 95% confidence interval [CI], 0.28 to 0.64; P<0.001)." · Bass N et al, 2010 PubMed
- "A breakthrough episode of hepatic encephalopathy occurred in 22.1% of patients in the rifaximin group, as compared with 45.9% of patients in the placebo group." · Bass N et al, 2010 PubMed
Research and Studies
8 PubMed-indexed papers reference Rifaximin. Top 8 shown.
Legal Status
Rifaximin is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is Rifaximin FDA-approved?
Rifaximin is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
How much research has been published on Rifaximin?
8 PubMed-indexed paper(s) reference Rifaximin in our current research feed. See the Research and Studies section above for citations.